Nano Dimension Ltd. filed a Form 8-K on August 18, 2026, reporting the appointment of Nadav Kidron as a Class II director and disclosing the expiration of an exclusivity period with Infinite Epigenetics, Inc.

Key Highlights

  • New Director: Nadav Kidron was appointed to the Board as a Class II director, effective August 16, 2026, with a term expiring at the 2026 annual stockholder meeting.
  • Independent Designation: The Board determined that Mr. Kidron qualifies as an independent director under applicable Nasdaq rules.
  • Committee Assignments: Mr. Kidron will serve on both the Audit Committee and the Compensation Committee.
  • Current Role: Mr. Kidron has served as President, Chief Executive Officer, and a director of Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) since March 2006, and as Chairman of Oramed's Board since June 2022.
  • Exclusivity Expired: The 30-day exclusivity period under a non-binding term sheet with Infinite Epigenetics, Inc. expired on July 15, 2026, and no definitive agreement has been reached as of the filing date.

Nano Dimension Board Addition and Infinite Epigenetics Update

According to the filing, Nano Dimension Ltd. (NASDAQ:NNDM) reported that its Board of Directors appointed Nadav Kidron as a Class II director on August 16, 2026, effective immediately. The term is set to expire on the date of the company's 2026 annual stockholder meeting, and Mr. Kidron will serve until his successor is duly elected and qualified, or until his earlier resignation or removal, the filing states.

The filing describes Mr. Kidron's professional background as including his current role as President, Chief Executive Officer, and director of Oramed Pharmaceuticals Inc. since March 2006, and Chairman of Oramed's Board since June 2022. The filing also notes that he has served on the board of directors of Lifeward Ltd. (Nasdaq: LFWD) since March 2026, as Chairman of the board of Oravax Medical Inc. since March 2021, and as a director of Alpha Tau Medical Ltd. (Nasdaq: DRTS) since May 2025. He also serves as Chairman of MDG Real Estate Global Ltd. since July 2024, according to the filing. Mr. Kidron holds an LLB and an International MBA from Bar-Ilan University, Israel, the filing states.

As a non-employee director, the filing discloses that Mr. Kidron will be compensated in accordance with the company's director compensation arrangements, as described in the company's Proxy Statement furnished on Form 6-K to the SEC on October 21, 2025. The company will also enter into an indemnification agreement with Mr. Kidron in substantially the same form as those entered into with other directors. Separately, under Item 7.01, the filing disclosed that the 30-day exclusivity period under a non-binding term sheet with Infinite Epigenetics, Inc. expired on July 15, 2026, and "as of the date hereof, the parties have not reached an agreement on the terms of a definitive agreement."

What Was Disclosed

Nano Dimension reported the appointment of Nadav Kidron to its Board as an independent Class II director, his committee assignments, and compensation terms, and separately disclosed that an exclusivity period with Infinite Epigenetics, Inc. expired without a definitive agreement.